Hermans Greet, De Jonghe Bernard, Bruyninckx Frans, Van den Berghe Greet
Department of Cellular and Molecular Medicine, KU Leuven, Herestraat 49, 3000 Leuven, Leuven, Belgium.
Cochrane Database Syst Rev. 2014 Jan 30;2014(1):CD006832. doi: 10.1002/14651858.CD006832.pub3.
Critical illness polyneuropathy or myopathy (CIP/CIM) is a frequent complication in the intensive care unit (ICU) and is associated with prolonged mechanical ventilation, longer ICU stay and increased mortality. This is an interim update of a review first published in 2009 (Hermans 2009). It has been updated to October 2011, with further potentially eligible studies from a December 2013 search characterised as awaiting assessment.
To systematically review the evidence from RCTs concerning the ability of any intervention to reduce the incidence of CIP or CIM in critically ill individuals.
On 4 October 2011, we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE, and EMBASE. We checked the bibliographies of identified trials and contacted trial authors and experts in the field. We carried out an additional search of these databases on 6 December 2013 to identify recent studies.
All randomised controlled trials (RCTs), examining the effect of any intervention on the incidence of CIP/CIM in people admitted to adult medical or surgical ICUs. The primary outcome was the incidence of CIP/CIM in ICU, based on electrophysiological or clinical examination. Secondary outcomes included duration of mechanical ventilation, duration of ICU stay, death at 30 and 180 days after ICU admission and serious adverse events from the treatment regimens.
Two authors independently extracted the data and assessed the risk of bias in included studies.
We identified five trials that met our inclusion criteria. Two trials compared intensive insulin therapy (IIT) to conventional insulin therapy (CIT). IIT significantly reduced CIP/CIM in the screened (n = 825; risk ratio (RR) 0.65, 95% confidence interval (CI) 0.55 to 0.77) and total (n = 2748; RR 0.70, 95% CI 0.60 to 0.82) population randomised. IIT reduced duration of mechanical ventilation, ICU stay and 180-day mortality, but not 30-day mortality compared with CIT. Hypoglycaemia increased with IIT but did not cause early deaths.One trial compared corticosteroids with placebo (n = 180). The trial found no effect of treatment on CIP/CIM (RR 1.27, 95% CI 0.77 to 2.08), 180-day mortality, new infections, glycaemia at day seven, or episodes of pneumonia, but did show a reduction of new shock events.In the fourth trial, early physical therapy reduced CIP/CIM in 82/104 evaluable participants in ICU (RR 0.62. 95% CI 0.39 to 0.96). Statistical significance was lost when we performed a full intention-to-treat analysis (RR 0.81, 95% CI 0.60 to 1.08). Duration of mechanical ventilation but not ICU stay was significantly shorter in the intervention group. Hospital mortality was not affected but 30- and 180-day mortality results were not available. No adverse effects were noticed.The last trial found a reduced incidence of CIP/CIM in 52 evaluable participants out of a total of 140 who were randomised to electrical muscle stimulation (EMS) versus no stimulation (RR 0.32, 95% CI 0.10 to 1.01). These data were prone to bias due to imbalances between treatment groups in this subgroup of participants. After we imputed missing data and performed an intention-to-treat analysis, there was still no significant effect (RR 0.94, 95% CI 0.78 to 1.15). The investigators found no effect on duration of mechanical ventilation and noted no difference in ICU mortality, but did not report 30- and 180-day mortality.We updated the searches in December 2013 and identified nine potentially eligible studies that will be assessed for inclusion in the next update of the review.
AUTHORS' CONCLUSIONS: There is moderate quality evidence from two large trials that intensive insulin therapy reduces CIP/CIM, and high quality evidence that it reduces duration of mechanical ventilation, ICU stay and 180-day mortality, at the expense of hypoglycaemia. Consequences and prevention of hypoglycaemia need further study. There is moderate quality evidence which suggests no effect of corticosteroids on CIP/CIM and high quality evidence that steroids do not affect secondary outcomes, except for fewer new shock episodes. Moderate quality evidence suggests a potential benefit of early rehabilitation on CIP/CIM which is accompanied by a shorter duration of mechanical ventilation but without an effect on ICU stay. Very low quality evidence suggests no effect of EMS, although data are prone to bias. Strict diagnostic criteria for CIP/CIM are urgently needed for research purposes. Large RCTs need to be conducted to further explore the role of early rehabilitation and EMS and to develop new preventive strategies.
危重病性多发性神经病或肌病(CIP/CIM)是重症监护病房(ICU)常见的并发症,与机械通气时间延长、ICU住院时间延长及死亡率增加相关。这是一篇首次发表于2009年(Hermans 2009)的综述的中期更新。更新至2011年10月,2013年12月检索到的其他可能符合条件的研究被列为待评估状态。
系统评价随机对照试验(RCT)的证据,以确定任何干预措施降低危重症患者发生CIP或CIM的能力。
2011年10月4日,我们检索了Cochrane神经肌肉疾病组专业注册库、Cochrane系统评价数据库、MEDLINE和EMBASE。我们检查了已识别试验的参考文献,并联系了试验作者和该领域的专家。2013年12月6日,我们对这些数据库进行了额外检索,以识别近期研究。
所有随机对照试验(RCT),研究任何干预措施对入住成人内科或外科ICU患者CIP/CIM发生率的影响。主要结局是基于电生理或临床检查的ICU中CIP/CIM的发生率。次要结局包括机械通气时间、ICU住院时间、ICU入院后30天和180天的死亡率以及治疗方案的严重不良事件。
两位作者独立提取数据并评估纳入研究的偏倚风险。
我们识别出五项符合纳入标准的试验。两项试验比较了强化胰岛素治疗(IIT)与常规胰岛素治疗(CIT)。IIT在筛选人群(n = 825;风险比(RR)0.65,95%置信区间(CI)0.55至0.77)和全部随机人群(n = 2748;RR 0.70,95% CI 0.60至0.82)中显著降低了CIP/CIM。与CIT相比,IIT缩短了机械通气时间、ICU住院时间和180天死亡率,但未降低30天死亡率。IIT导致低血糖发生率增加,但未引起早期死亡。一项试验比较了皮质类固醇与安慰剂(n = 180)。该试验发现治疗对CIP/CIM(RR 1.27,95% CI 0.77至2.08)、180天死亡率、新发感染、第7天血糖或肺炎发作无影响,但确实显示新的休克事件有所减少。在第四项试验中,早期物理治疗在ICU的104名可评估参与者中的82名中降低了CIP/CIM(RR 0.62,95% CI 0.39至0.96)。当我们进行完全意向性分析时,统计学显著性消失(RR 0.81,95% CI 0.60至1.08)。干预组机械通气时间显著缩短,但ICU住院时间未显著缩短。医院死亡率未受影响,但30天和180天死亡率结果未提供。未观察到不良反应。最后一项试验发现,在总共140名随机分配接受电肌肉刺激(EMS)与不刺激的参与者中,52名可评估参与者的CIP/CIM发生率降低(RR 0.32,95% CI 0.10至1.01)。由于该亚组参与者治疗组之间的不平衡,这些数据容易产生偏倚。在我们对缺失数据进行插补并进行意向性分析后,仍然没有显著效果(RR 0.94,95% CI 0.78至1.15)。研究人员发现对机械通气时间无影响,且ICU死亡率无差异,但未报告30天和180天死亡率。
我们在2013年12月更新了检索,识别出九项可能符合条件的研究,将在该综述的下一次更新中评估其是否纳入。
两项大型试验提供了中等质量的证据表明强化胰岛素治疗可降低CIP/CIM,高质量证据表明其可缩短机械通气时间、ICU住院时间和180天死亡率,但代价是低血糖。低血糖的后果和预防需要进一步研究。中等质量的证据表明皮质类固醇对CIP/CIM无影响,高质量证据表明除了新的休克发作减少外,皮质类固醇不影响次要结局。中等质量的证据表明早期康复对CIP/CIM有潜在益处,同时伴有机械通气时间缩短,但对ICU住院时间无影响。极低质量的证据表明EMS无影响,尽管数据容易产生偏倚。迫切需要用于研究目的的CIP/CIM严格诊断标准。需要进行大型RCT以进一步探索早期康复和EMS的作用,并制定新的预防策略。